본문으로 건너뛰기
← 뒤로

Surgical management of giant Xp11.2 translocation renal cell carcinoma with multivisceral invasion: a case report of en bloc resection and targeted-immunotherapy success.

Frontiers in oncology 2025 Vol.15() p. 1709543

Luo B, Luo H

📝 환자 설명용 한 줄

A 36-year-old man presented with a 1-month history of abdominal distension and a 3-day palpable mass.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Luo B, Luo H (2025). Surgical management of giant Xp11.2 translocation renal cell carcinoma with multivisceral invasion: a case report of en bloc resection and targeted-immunotherapy success.. Frontiers in oncology, 15, 1709543. https://doi.org/10.3389/fonc.2025.1709543
MLA Luo B, et al.. "Surgical management of giant Xp11.2 translocation renal cell carcinoma with multivisceral invasion: a case report of en bloc resection and targeted-immunotherapy success.." Frontiers in oncology, vol. 15, 2025, pp. 1709543.
PMID 41613556

Abstract

A 36-year-old man presented with a 1-month history of abdominal distension and a 3-day palpable mass. Imaging demonstrated a 20-cm left renal tumor with adjacent organ infiltration and suspicious lymphadenopathy, radiologically suggestive of sarcoma or advanced malignancy. He underwent radical en bloc resection including left nephrectomy, distal pancreatectomy, splenectomy, and partial colectomy due to tumor invasion of the pancreatic tail, splenic vessels, and descending colon mesentery. Histopathology confirmed Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma. Surveillance MRI at 3 months postoperatively revealed local recurrence, prompting combination therapy with sunitinib (VEGF inhibitor) and sintilimab (anti-PD-1 antibody). Follow-up imaging demonstrated significant regression at 1 month, with no evidence of disease progression at 12-month reassessment.

같은 제1저자의 인용 많은 논문 (5)